Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
复制标题
异质染色体 12p 缺失是多发性骨髓瘤的独立不良预后因素，并且对基于硼替佐米的治疗具有耐药性
DOI：
10.18632/oncotarget.3319
复制
发表时间：
2015-04-20
期刊：
影响因子：
--
通讯作者：
Qiu L
中科院分区：
文献类型：
--
作者：
Li F;Xu Y;Deng P;Yang Y;Sui W;Jin F;Hao M;Li Z;Zang M;Zhou D;Gu Z;Ru K;Wang J;Cheng T;Qiu L
12 p缺失（del（12 p））是多发性骨髓瘤（MM）的一个新的阴性预后标志物，近年来受到越来越多的关注。然而，它对MM的影响仍然存在争议。在这项研究中，我们使用荧光原位杂交（FISH）对275例在前瞻性、非随机临床试验（BDH 2008/02）中接受治疗的新诊断MM病例进行了全面评估12 p13缺失的临床影响。结果显示，12 p13缺失在10.5%的新诊断病例中检测到，并且与高肿瘤负荷的多个指标相关，包括ISS III、BM浆细胞增多大于50%和肾损害。12 p13缺失的病例中del（17 p）、IGH易位和t（4;14）的发生率较高。del（12 p）患者的PFS和OS预后显著不良，即使是接受硼替佐米治疗的患者。当调整包括del（13 q）、del（17 p）、t（4;14）、amp（1 q21）、ISS分期和LDH在内的已建立的预后变量时，del（12 p13）仍然是PFS（P = 0.007）和OS（P = 0.032）的强有力的独立不利因素。此外，del（12 p13）与高β2-MG、高LDH和骨病变的联合检测可进一步识别具有高危特征的亚群。我们的研究结果有力地支持del（12 p13）可以作为MM的一个有价值的预后标志物。
The deletion of 12p (del(12p)) has been described as a novel negative prognostic marker in multiple myeloma (MM) and has gained increasing attention in recent years. However, its impact on MM is still controversial. In this study, we comprehensively evaluated the clinical impact of 12p13 deletion using fluorescence in situ hybridization (FISH) on 275 newly diagnosed MM cases treated in a prospective, non-randomized clinical trial (BDH 2008/02). The results showed that deletion of 12p13 was detected in 10.5% of newly diagnosed cases and associated with multiple indicators for high tumor burden including ISS III, BM plasmacytosis larger than 50%, and renal lesion. Moreover, the cases with 12p13 deletion typically had higher incidence of del(17p), IGH translocation and t(4;14). Patients with del(12p) conferred significantly adverse prognosis for PFS and OS, even in patients subjected to bortezomib-based therapy. When adjusted to the established prognostic variables including del(13q), del(17p), t(4;14), amp(1q21), ISS stage and LDH, del(12p13) remained the powerful independent adverse factor for PFS (P = 0.007) and OS (P = 0.032). In addition, del(12p13) combined with high β2-MG, high LDH and bone lesion can further identify subpopulations with high-risk features. Our results strongly supported that del(12p13) can be used as a valuable prognostic marker in MM.
登录
查看更多内容
影响因子：
20.3
作者：
Davies, FE;Dring, AM;Anderson, KC
通讯作者：
Anderson, KC
染色体 1q21 增加导致用硼替佐米治疗的多发性骨髓瘤预后较差，但拷贝数变异和所涉及浆细胞的百分比没有额外的预后价值
影响因子：
10.1
作者：
An, Gang;Xu, Yan;Qiu, Lugui
通讯作者：
Qiu, Lugui
影响因子：
13
作者：
Xie, Ping;Kraus, Zachary J.;Bishop, Gail A.
通讯作者：
Bishop, Gail A.
影响因子：
20.3
作者：
Zhan, FH;Hardin, J;Shaughnessy, J
通讯作者：
Shaughnessy, J
影响因子：
45.3
作者：
Avet-Loiseau, Herve;Li, Cheng;Minvielle, Stephane
通讯作者：
Minvielle, Stephane